Bladder cancer paclitaxel drug-resistant organ model and establishment method thereof
By isolating organoids from fresh bladder cancer tissues and induced drug resistance by increasing drug concentration, the problem of long construction cycle of bladder cancer cell resistance model in the prior art was solved, and an efficient bladder cancer paclitaxel resistance organoid model was established. , used to study drug resistance mechanisms and support clinical treatment.
Patent Information
- Application Number
- CN202411483766.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-23
- Publication Date
- 2024-12-06
AI Technical Summary
The existing bladder cancer cell drug resistance model construction cycle is too long to meet the urgent needs of clinical chemotherapy regimens, and cannot accurately reflect the complexity of human tumors, and cannot effectively study drug resistance mechanisms.
By isolating organoids from fresh bladder cancer tissues, using the IC50 value of paclitaxel for drug resistance induction culture, and induced drug resistance culture again by increasing drug concentration method to establish a paclitaxel-resistant organoid model for bladder cancer, shortening the construction cycle and improving the success rate.
The successful construction of paclitaxel-resistant organoid model of bladder cancer within 6-7 months has maintained the morphological consistency of the organoid, provided an efficient research tool for drug resistance mechanisms, and provided an ideal model for clinical treatment.
Smart Images

Figure CN119082036A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of tumor biology, and specifically relates to a bladder cancer paclitaxel-resistant organoid model and an establishment method thereof. Background Art
[0002] Drug resistance models include in vivo models and in vitro models. Cell lines are the most commonly used in vitro models for studying drug resistance mechanisms. In vivo drug resistance models include transplantation-type and induction-type. Transplantation-type drug resistance models involve injecting drug-resistant cells or tissues directly into animals, while induction-type models are similar to induction of drug resistance in vitro, where drugs are injected into tumor-bearing animals and drug-resistant animal models are obtained through repeated administration.
[0003] Chemotherapy is one of the most effective methods for treating cancer patients, but chemotherapy resistance is a common problem in clinical anti-tumor treatment. Many cancer patients' condition is quickly relieved when they first take the drug, but long-term treatment will produce drug resistance, which is a major factor in the difficulty of curing cancer patients. If patients continue to take the drug after becoming resistant, the drug will not only fail to relieve the condition, but also have a series of toxic side effects. In order to simulate clinical drug use and explore the causes of drug resistance in cancer patients, a series of drug resistance models for mechanism research have been studied and applied one after another.
[0004] Similar to other cancers, most bladder cancer patients begin to experience poor drug response after a certain number of chemotherapy cycles. Cell lines and mouse models are commonly used models for exploring the mechanism of bladder cancer resistance, and can directly induce cell resistance for mechanism research. However, current methods of inducing resistance take half a year to a year or longer. After stopping the drug action, the cell resistance phenotype can last for weeks or months, after which the cells must be re-exposed to the drug to restore resistance. The cycle of inducing resistance is usually long. Some studies do not use drug-induced resistance models, but directly compare the drug sensitivity of several cancer cell lines, and select relatively sensitive or resistant tumor cell lines for resistance mechanism research. However, due to the lack of human-specific tumor microenvironment and extracellular matrix, cancer cells cannot accurately reproduce the complexity of human cancer, whether grown in culture or as xenografts, and cannot reflect the changes in the genome and epigenetics of different tumor cells. Although xenograft models can retain the inter-tumor heterogeneity and intra-tumor heterogeneity of tumors, they are difficult to model and have a low success rate. More importantly, the tumor transplant modeling cycle is too long to meet the clinical needs of formulating chemotherapy plans after surgery, and it is not convenient for in vitro molecular mechanism research. Summary of the invention
[0005] In view of this, the purpose of the present invention is to provide a method for establishing a paclitaxel-resistant organoid model of bladder cancer, by screening for bladder cancer-resistant organoids through a drug screening method that induces cell resistance, which is resistant to paclitaxel and has a short construction cycle time.
[0006] The present invention provides a method for establishing a paclitaxel-resistant organoid model of bladder cancer, comprising the following steps:
[0007] Isolation of organoids from fresh bladder cancer tissue;
[0008] Paclitaxel IC in organoids 50 The organoid is cultured for drug resistance induction with the initial drug concentration as the value, so as to obtain initial drug-resistant organoid;
[0009] The initial drug-resistant organoids were induced to culture again with drug resistance using the drug concentration increasing method to obtain a paclitaxel-resistant organoid model of bladder cancer.
[0010] Preferably, the method for isolating organoids from fresh bladder cancer tissue comprises digesting the fresh bladder cancer tissue with a first digestion solution until it is transparent, neutralizing it, digesting the transparent bladder cancer tissue with a second digestion solution, and neutralizing it again to obtain the organoids;
[0011] The first digestion solution is an aqueous solution containing the following components: 2-10 mg / ml collagenase II, 5-20 μM Y27632, 50-200 μg / ml DNase I and 1-5 mg / ml neutral protease;
[0012] The second digestion solution is an aqueous solution containing the following components: 50% to 100% stable trypsin replacement enzyme and 5 to 20 μM Y27632;
[0013] The neutralization solution for neutralization treatment is based on DMEM culture medium and also includes the following components in volume percentage: 10% to 20% fetal bovine serum (FBS) and 0.8% to 1.2% acrylic acid.
[0014] Preferably, the temperature condition of the first digestion liquid digestion is 36-38°C water bath, and the time is 30-60min;
[0015] The temperature condition of the second digestion liquid digestion is 36-38°C water bath, and the time is 4-6 minutes.
[0016] Preferably, the paclitaxel IC of the organoid is 50 The value is 4~7nM.
[0017] Preferably, the method of drug resistance induction culture is to perform cyclic culture according to a cycle of first administering the drug for 2 to 3 days and then stopping the drug for 3 to 4 days;
[0018] The drug resistance induction culture lasts for 6 to 7 months.
[0019] Preferably, the concentration of paclitaxel used to induce drug-resistant culture again is 7-10 nM, 10-13 nM and 16-19 nM;
[0020] The total time of the re-induction of drug-resistant culture lasts for 6 to 7 months.
[0021] Preferably, after the second neutralization treatment, the process further includes removing impurities from the neutralization product.
[0022] Preferably, the impurity removal method is membrane filtration and collecting the filtrate;
[0023] The pore size of the filter membrane is 75 μM or 100 μM.
[0024] The present invention provides a bladder cancer paclitaxel-resistant organoid model obtained by the establishment method, which is resistant to paclitaxel.
[0025] The present invention provides application of the bladder cancer paclitaxel-resistant organoid model in screening or developing anti-tumor drugs.
[0026] The present invention provides a method for establishing a paclitaxel-resistant organoid model of bladder cancer. The present invention can successfully induce paclitaxel-resistant organoids of bladder cancer within 6 to 7 months by imitating the construction method of cell-resistant strains, with a high success rate. In addition, the morphology of the established bladder cancer organoids is basically consistent with that of their parent organoids, providing an ideal model for the research and development of therapeutic drugs for paclitaxel resistance, and laying the foundation for clinical treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The paclitaxel dose-response curves of three bladder cancer organoids (A-C) and the final fitted IC of paclitaxel for six days 50 Value(D);
[0028] Figure 2 This is a timeline diagram of drug addition for three organoids (BCO-1, BCO-2, and BCO-3);
[0029] Figure 3 The paclitaxel dose-response curves of three bladder cancer organoids before and after induction of drug resistance (A-C) and the fitted paclitaxel IC 50 Value (D); Sen represents organoids that have not been treated with drugs, and Res represents organoids that have been induced to resist paclitaxel;
[0030] Figure 4 The paclitaxel dose-response curves of three bladder cancer organoids before and after drug resistance (A-C) and the fitted paclitaxel IC 50Values and corresponding resistance index (D); Sen represents organoids that have not been treated with drugs, Res represents paclitaxel-resistant organoids, and Resistance Index (RI) represents the resistance index;
[0031] Figure 5 The images show the morphology of three bladder cancer organoids before and after drug resistance under a microscope (A) and after HE staining (B); Sen represents organoids that have not been treated with drugs, and Res represents paclitaxel-resistant organoids. DETAILED DESCRIPTION
[0032] The present invention provides a method for establishing a paclitaxel-resistant organoid model of bladder cancer, comprising the following steps:
[0033] Isolation of organoids from fresh bladder cancer tissue;
[0034] Paclitaxel IC in organoids 50 The value is the initial drug concentration for drug resistance induction culture to obtain the initial drug-resistant organoids;
[0035] The initial drug-resistant organoids were induced to culture again with drug resistance using the drug concentration increasing method to obtain a paclitaxel-resistant organoid model of bladder cancer.
[0036] The present invention isolates organoids from fresh bladder cancer tissue.
[0037] In the present invention, the method for isolating organoids from fresh bladder cancer tissue preferably comprises digesting the fresh bladder cancer tissue with a first digestion solution until it is transparent, neutralizing it, digesting the transparent bladder cancer tissue with a second digestion solution, and neutralizing it again to obtain organoids. The first digestion solution is preferably an aqueous solution containing the following components: 2-10 mg / ml collagenase II, 5-20 μM Y27632, 50-200 μg / ml DNaseⅠ and 1-5 mg / ml neutral protease; more preferably 5 mg / ml collagenase II, 10 μM Y27632, 100 μg / DNaseⅠ and 2 mg / ml neutral protease. The temperature condition for digestion with the first digestion solution is preferably a 36-38°C water bath, more preferably a 37°C water bath; the time is preferably 30-60 min, more preferably 40-50 min, and most preferably 45 min. The role of the first digestion solution digestion is to hydrolyze intercellular matrix components such as collagen in connective tissue and disperse tumor tissue. The neutralization solution for neutralization treatment is preferably based on DMEM culture medium, and also includes the following components in volume percentage concentration: 10% to 20% FBS and 0.8% to 1.2% acrylic acid, more preferably 15% FBS and 1.0% acrylic acid. The role of the neutralization treatment is to terminate the digestion effect of the first digestion solution. The second digestion solution is preferably an aqueous solution containing the following components: a mass percentage concentration of 50% to 100% stable trypsin replacement enzyme and 5 to 20 μM Y27632; more preferably 100% stable trypsin replacement enzyme and 10 μM Y27632. The temperature condition for digestion with the second digestion solution is preferably a 36 to 38°C water bath, more preferably a 37°C water bath. The time is preferably 4 to 6 minutes, more preferably 5 minutes. The role of digestion with the second digestion solution is to digest tumor tissue and disperse the tumor tissue into single tumor cells.
[0038] After obtaining the organoids, the present invention uses paclitaxel IC 50 The organoid is cultured for drug resistance induction with the initial drug concentration as the value, so as to obtain initial drug-resistant organoid;
[0039] In the present invention, the paclitaxel IC 50 The value is preferably 4 to 7 nM. The method of drug resistance induction culture is preferably to perform cyclic culture in a cycle of first administering the drug for 2 to 3 days and then stopping the drug for 3 to 4 days. The drug resistance induction culture preferably lasts for 6 to 7 months.
[0040] After obtaining the initial drug-resistant organoids, the present invention uses the drug concentration increasing method to induce drug-resistant culture again on the initial drug-resistant organoids to obtain a paclitaxel-resistant organoid model of bladder cancer.
[0041] In the present invention, whether to use the drug concentration increasing method to induce drug resistance culture again depends on the growth state of the organoid. If the organoid gradually adapts to the current drug concentration and maintains a good growth state, the drug concentration can be increased to induce drug resistance culture again. The paclitaxel concentration for inducing drug resistance culture again is preferably 7-10nM, 10-13nM and 16-19nM, more preferably 8-9nM, 11-12nM and 17-18nM. After completing at least two stages of increasing drug concentration culture, test the IC before and after increasing the drug concentration. 50 If the IC 50 If the value is partially improved, it indicates that the drug resistance can be improved by continuing to increase the drug concentration, otherwise, stop increasing the drug concentration. The total time of the re-inducing drug resistance culture is preferably 6 to 7 months.
[0042] In the present invention, after the second neutralization treatment, it is preferred to further include removing impurities from the neutralization product. The method for removing impurities is preferably to filter with a filter membrane and collect the filtrate; the pore size of the filter membrane is preferably 75 μM or 100 μM. After inducing drug resistance culture again, the IC 50 The values changed significantly and the resistance index was greater than 3, indicating that the induced cultured organoids were paclitaxel-resistant organoids and could be used to study the resistance mechanism.
[0043] The present invention provides a bladder cancer paclitaxel-resistant organoid model obtained by the establishment method, which is resistant to paclitaxel.
[0044] In the present invention, the morphology of the bladder cancer paclitaxel-resistant organoid model is basically the same as that of the organoid without drug treatment, but the volume is slightly smaller than that of the organoid without drug treatment. At the same time, the HE staining results show that the bladder cancer paclitaxel-resistant organoid model retains the tumor characteristics of the organoid, such as nuclear dark staining, increased nuclear-cytoplasmic ratio, etc., but the cells are arranged more sparsely and loosely.
[0045] In the present invention, the IC of paclitaxel in the bladder cancer paclitaxel-resistant organoid model 50 It is 13-19nM, which is higher than before inducing drug resistance culture.
[0046] The present invention provides application of the bladder cancer paclitaxel-resistant organoid model in screening or developing anti-tumor drugs.
[0047] The bladder cancer paclitaxel-resistant organoid model described in the present invention is used as an experimental material to carry out drug screening and development.
[0048] The following is a detailed description of a bladder cancer paclitaxel-resistant organoid model and a method for establishing the same provided by the present invention in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.
[0049] Example 1
[0050] Organoid culture
[0051] 1. Fresh Tissue Processing and Organoid Cultivation
[0052] 1) Before processing the tissue, you need to prepare. Heat the first digestion solution (5mg / ml collagenase II + 10μM Y27632 + 100μg / ml DNase I + 2mg / ml neutral protease), the second digestion solution (100% stable trypsin replacement enzyme (TrypLE Express) + 10μM Y27632), the neutralization solution (DMEM medium + 20% FBS + 1% acrylic acid (AA)) and the bladder cancer organoid culture medium in a 37℃ water bath. Melt the subpackaged matrix gel in a 4℃ refrigerator 2h in advance and place it in an ice box during the experiment. Preheat the six-well plate in the incubator and sterilize it with ultraviolet light in the biosafety cabinet 30min in advance. Wear lab coats, sterile gloves and masks. Dilute the matrigel with advanced DMEM (reduced serum medium) 2h in advance and spread it on the bottom of the well plate.
[0053] 2) Bladder cancer patient samples obtained through surgical resection need to be placed in a special preservation solution, labeled with patient information, and sent to the laboratory as soon as possible. After the sample is sent to the laboratory, in the biosafety cabinet, take out the tissue block and place it in a six-well plate. Use a ruler to record the length and width of the sample. If the tissue sample is small or finely divided, the sample can be precipitated to the bottom of the centrifuge tube by centrifugation.
[0054] 3) Take an appropriate amount of PBS into three wells of a six-well plate, pick up the sample with tweezers, and use a sterile Pasteur pipette to absorb PBS to repeatedly wash the tissue to remove fat and connective tissue, completing the washing process in three wells in turn.
[0055] 4) Clamp all washed tissues onto the lid of the six-well plate, take a small piece of tissue and put it into a cryopreservation tube, fix it with paraformaldehyde, and store it in a refrigerator at 4°C. This tissue will be used for subsequent immunohistochemistry experiments.
[0056] 5) Use sterilized scissors to cut the remaining tissue into small pieces.
[0057] 6) Take a small portion of the chopped tissue and place it in a cryovial for sequencing, label it, and freeze it quickly in a -80°C freezer.
[0058] 7) The remaining tissue is used to culture organoids: Place the tissue in a 15 ml centrifuge tube containing 5 ml of the first digestion solution, digest it in a 37°C water bath for 30 to 60 minutes, shake the tissue back and forth in the water bath to ensure full digestion, and finally digest it until the tissue becomes transparent.
[0059] 8) Rinse the six-well plate covered with diluted matrix gel prepared before the experiment with PBS.
[0060] 9) Transfer all the digested tissues into a 15 ml centrifuge tube and centrifuge (1200 rpm, 5 min).
[0061] 10) Pour off the supernatant, add 4 ml of the second digestion solution into the centrifuge tube, and digest in a 37°C water bath for 5 min.
[0062] 11) Add 4 ml of neutralizing solution into the centrifuge tube and centrifuge (1200 rpm, 5 min).
[0063] 12) After centrifugation, add neutralizing solution again and gently pipette the tissue.
[0064] 13) Place a 75 μM or 100 μM filter membrane in a new six-well plate, filter all the cell suspension, transfer the filtrate to a new 15 ml centrifuge tube, and centrifuge (1200 rpm, 5 min).
[0065] 14) Aspirate and discard the supernatant, rinse the cells with 1 ml of organoid culture medium, and centrifuge (1200 rpm, 5 min).
[0066] 15) Mix the matrix gel and drop it into the well plate. Turn the six-well plate over and place it in the incubator for 10 minutes to wait for solidification. Add organoid culture medium and change the medium the next day.
[0067] 2. Passaging of Organoids
[0068] 1) Observe the status of organoids under a microscope.
[0069] Before subculturing, prepare the digestion solution (50ml TrypLE Express + 5μl Y27632) and neutralization solution (DMEM medium + 20% FBS + 1% AA), as well as bladder cancer organoid culture medium, in a 37°C water bath to preheat. Place the subpackaged matrix gel in a 4°C refrigerator to melt 2 hours in advance and place it in an ice box during the experiment. Preheat the six-well plate in the incubator. Sterilize with ultraviolet light in the biosafety cabinet 30 minutes in advance. Wear lab coats, sterile gloves, and masks.
[0070] 2) Take out the six-well plate containing organoids from the incubator, carefully aspirate the culture medium, add 2 ml of digestion solution to each well of organoids, and gently blow the organoids to disperse them. Place the six-well plate in the incubator and digest for 7 to 10 minutes depending on the state of the organoids. During the digestion, the size of the organoids can be observed under a microscope.
[0071] 3) After digestion for an appropriate time, add an equal volume of neutralizing solution to terminate digestion. Transfer the digested and neutralized organoids to a 15 ml centrifuge tube and centrifuge for 5 minutes at 1200 rpm.
[0072] 4) Aspirate and discard the supernatant, add 1 ml of bladder cancer organoid culture medium to wash the organoids, and gently blow the precipitate with a pipette (try to use a small volume pipette tip to reduce organoid damage). Centrifuge for 5 minutes at 1200 rpm and aspirate and discard the supernatant.
[0073] 5) If the ratio of 1:2 is used for passaging, each well of organoids needs to be resuspended in 50μl of culture medium, and then 550μl of matrix gel is added to mix by pipetting. Avoid bubbles when pipetting, and drip the gel drop by drop into the preheated six-well plate. The volume of each drop should be within 20-30μl; after standing for one minute, turn the six-well plate over and put it in the incubator for 10 minutes to wait for the matrix gel to solidify. After solidification, add 2-3ml of culture medium to each well. To reduce evaporation, add PBS to the blank well. Change the medium every 2-3 days after passaging.
[0074] 3. Organoid Recovery
[0075] 1) Before thawing the organoids, you need to prepare them. Heat the neutralization solution and bladder cancer organoid culture medium in a 37°C water bath. Melt the subpackaged matrix gel in a 4°C refrigerator 2 hours in advance and place it in an ice box during the experiment. Preheat the six-well plate in an incubator and sterilize it with a UV lamp in a biosafety cabinet 30 minutes in advance. Wear lab coats, sterile gloves, and masks.
[0076] 2) Remove the organoid cryovial from the liquid nitrogen tank and quickly thaw it in a 37°C water bath. Shake the cryovial for about 2 minutes to increase its thawing rate.
[0077] 3) Transfer the cryopreservation solution mixed with organoids in the cryopreservation tube to a 15 ml centrifuge tube containing 2-3 ml of neutralizing solution and centrifuge for 5 minutes at 1200 rpm.
[0078] 4) Aspirate and discard the supernatant, add 1 ml of bladder cancer organoid culture medium, gently pipette the precipitate to resuspend it, and centrifuge (1200 rpm, 5 min).
[0079] 5) Aspirate the supernatant and add 550 μl of matrix gel, gently blowing to avoid bubbles. Drop the matrix gel into the preheated six-well plate, 20-30 μl per drop. After dropping, let it stand for 1 minute, then turn the six-well plate upside down and put it in the incubator for 10 minutes to allow the matrix gel to solidify. After the matrix gel solidifies, add 2-3 ml of culture medium to each well. To reduce evaporation, add PBS to the blank well.
[0080] 6) Change the medium every 2-3 days.
[0081] 4. Organoid Cryopreservation
[0082] 1) Observe the state of organoids under a microscope. Prepare before freezing, preheat the digestion solution (50ml TrypLE Express + 5μl Y27632) and neutralization solution (DMEM medium + 20% FBS + 1% AA) in a 37℃ water bath, and take out the freezing solution from the -20℃ refrigerator to thaw.
[0083] 2) Take out the six-well plate containing organoids from the incubator and carefully aspirate the culture medium. Add 2 ml of digestion solution to each well of organoids, gently blow the organoids to disperse them, and place them in the incubator for 7 minutes after adding the digestion solution. The digestion of the organoids can be observed under a microscope during the digestion process (do not digest frozen organoids too small). After digestion, take out the six-well plate and add an equal volume of neutralization solution to each well of the organoids to terminate the digestion process.
[0084] 3) Transfer the digested organoids to a new 15 ml centrifuge tube and centrifuge (5 min, 1200 rpm).
[0085] 4) Aspirate the supernatant, add freezing solution, blow and hit the precipitate to resuspend and mix, and dispense into cryopreservation tubes, 1-1.5 mL per tube, and mark the organoid information.
[0086] 5) Place the cryovials in a gradient cooling box, place in a -80°C refrigerator overnight, and transfer to a liquid nitrogen tank the next day.
[0087] 5. Drug IC in Organoids 50 Detection
[0088] ① Organoid plating was performed on the first day.
[0089] 1) Before plating, prepare the plates by placing the digestion solution (50ml TrypLE Express + 5μl Y27632), neutralization solution (DMEM medium + 20% FBS + 1% AA) and bladder cancer organoid culture medium in a 37°C water bath. Melt the packaged matrix gel in a 4°C refrigerator in advance and place it in an ice box during the experiment. Sterilize the biosafety cabinet with UV light 30 minutes in advance. Wear lab coats, sterile gloves and masks.
[0090] 2) Take out the six-well plate containing organoids from the incubator, observe the state of the organoids under a microscope, and determine the number of organoids required for the experiment. Use the bottom of a 1ml pipette to scrape a certain number of organoids, transfer them to a 15ml centrifuge tube, and centrifuge for 5 minutes at 1200 rpm.
[0091] 3) Discard the supernatant, add 2 ml of digestion solution, and digest in a 37°C water bath for 7-10 min. After digestion is complete, add an equal volume of neutralizing solution to terminate digestion, and centrifuge for 5 min at 1200 rpm.
[0092] 4) Aspirate and discard the supernatant, add organoid culture medium, add 2%-5% matrix gel according to the volume of the culture medium, and gently pipette to mix the organoids.
[0093] 5) Evenly add the organoid suspension to a low-adsorption 96-well plate, 100 μl per well. To avoid edge effects, the edge of the 96-well plate is not used for the experiment. In addition, three blank control wells with only culture medium are set up. To reduce evaporation, add PBS around the well plate. After laying the plate, put the 96-well plate into a constant temperature box for incubation.
[0094] ②The next day, the organoids were treated with drugs.
[0095] Preheat the bladder cancer organoid culture medium in a 37°C water bath in advance. According to the experimental needs, six paclitaxel drug concentrations of 10μm, 1μm, 100nm, 10nm, 1nm, and 100pm were set, and the corresponding solutions were prepared with the culture medium. Since the paclitaxel stock solution is dissolved in dimethyl sulfoxide (DMSO), it is necessary to ensure that each concentration of the drug contains the same dose of DMSO during preparation, and the same dose of DMSO must be set as a control group. Add the culture medium containing different paclitaxel doses to the well plate, set 3-5 replicate wells for each concentration, and 100μl per well. After all are added, place the 96-well plate in an incubator and culture for six days.
[0096] ③Use on the seventh day 3D luminescence method was used to detect cell viability.
[0097] In advance Thaw the 3D cell viability detection reagent from the -20℃ refrigerator. Add the detection reagent in the same volume as the culture medium (before the experiment, 3D cell viability detection reagent was mixed evenly to avoid undissolved reagent powder at the bottle mouth). After shaking and mixing for 5 minutes, incubated at room temperature for 30 minutes and detected the chemiluminescence value using a multifunctional microplate reader. The cell viability values of different drug concentrations were calculated based on the obtained values. The calculation formula I is as follows:
[0098] Cell viability = {A (加药) -A (空白)} / {A (0加药) -A (空白)}×100Formula I.
[0099] Among them, A (加药) is the luminescence value of the wells with cells treated with drug solution, A (空白) is the luminescence value of the wells containing neither cells nor drug solution, A (0加药) is the luminescence value of the wells containing cells not treated with drugs.
[0100] ④ Calculate IC using GraphPadPrism 8 50Open GraphPadPrism 8 software, click the "Grouped" option in the new chart on the left side of the page, select "Enter 3 duplicate values in side-by-side subcolumns", fill in the cell viability values and corresponding drug concentration values calculated in the previous step into the table, click "Analysis", select "Nonlinear Regression (Curve Fitting)" in "XY Analysis", click "OK", select the corresponding formula in "Dose-Response-Inhibition" in the pop-up page, and click "OK" to get the fitted IC 50 value.
[0101] 6. Inducing drug resistance in organoids
[0102] Bladder cancer organoids that have been successfully identified, have good growth status, and can be stably passaged were selected for expansion culture. Organoids were plated in 96-well low-adsorption plates, and 6 different concentrations of bladder were tested, with 3 replicates for each concentration. The cell viability values corresponding to each well were calculated, and the drug sensitivity curves of each bladder cancer organoid were obtained by analysis with GraphPad Prism 8 software, and the initial IC values of each bladder cancer organoid were calculated. 50 The initial IC of each bladder cancer organoid was 50 The value was used as the starting drug screening concentration to induce organoid resistance, and intermittent drug administration was performed in a pattern of 2-3 days of drug action and 2-3 days of drug withdrawal. The drug concentration was then gradually increased according to the growth status of the organoids. After at least 2 drug concentration increases, the initial untreated organoids and drug-induced organoids were plated in a 96-well plate, and the cell viability values at 6 different concentrations were tested to obtain the drug sensitivity curve of each bladder cancer organoid, and the IC 50 By comparing the IC 50 The value is used to determine whether the organoid has a drug resistance trend after a period of drug induction. The drug resistance index, that is, the IC value of the drug-resistant organoid 50 IC values of organoids without drug induction 50 The ratio of is used as an indicator to judge whether the cells are resistant. If the organoid resistance index is less than 3, the drug concentration is increased to screen for organoid resistant strains. In the process of inducing resistance, the IC test is still passed. 50 The value is compared with its degree of drug resistance. When the test result shows that the drug resistance index is greater than 3, it is considered that the organoid has successfully induced drug resistance and passed the IC 50 Paclitaxel with different values was used to act on the initial bladder cancer organoids and the resistant bladder cancer organoids, and the cell death of the organoids was observed.
[0103] 7. Paraffin Embedding of Organoids
[0104] 1) Before fixing the organoids, you need to prepare them. Put the PBS in a 4℃ refrigerator in advance and sterilize it with UV light in the biosafety cabinet 30 minutes in advance. Wear lab coats, sterile gloves, and masks. For embedding, melt the wax in advance and put the necessary tools in the incubator.
[0105] 2) Take out the organoids from the incubator and observe their growth status. After aspirating the organoid culture medium, add 1 ml of paraformaldehyde, gently blow the matrix gel droplets to remove them from the well plate, and transfer the solution to a 1.5 ml EP tube.
[0106] 3) After gentle mixing, incubate on ice for more than 1 hour; centrifuge (4°C, 1500 rpm, 5 min), and carefully aspirate out the paraformaldehyde.
[0107] 4) Add pre-cooled PBS for washing, centrifuge (4°C, 1500 rpm, 5 min), aspirate PBS, and repeat this step twice or more.
[0108] 5) Resuspend the organoids with paraformaldehyde and fix them overnight (4°C, shaking), centrifuge after fixation (1500 rpm, 5 min), and aspirate the paraformaldehyde.
[0109] 6) Weigh agarose powder to prepare 2% agarose gel and put it in a 15ml centrifuge tube. Mix the agarose powder and heat the liquid in a microwave until it is transparent. At the same time, heat a cup of water (immerse the centrifuge tube containing agarose in it to prevent it from solidifying too quickly). Prepare a clean plate, take 100-300μl of agarose gel according to the number of organoids and add it to the centrifuge tube containing organoids, cut off a part of the front end of the gun tip (to avoid damaging the organoids), take about 100μl of gel and drop it on the plate to form a hemisphere. Avoid bubbles in this process, let it stand to solidify, use a blade to move the organoid from the bottom to the 2ml EP tube, and put it in a -20℃ refrigerator to accelerate the solidification of the agarose gel.
[0110] 7) Move the gel hemisphere containing the organoids into an EP tube filled with 70% ethanol and place it on a decolorizing shaker for 1 hour (if not fixed immediately, place it in a 4°C refrigerator).
[0111] 8) Aspirate and discard 70% ethanol, add 80% ethanol, and place on a decolorizing shaker for 1 hour.
[0112] 9) Aspirate 80% ethanol, add 95% ethanol, and place on a decolorizing shaker for 1 hour.
[0113] 10) Aspirate 95% ethanol, add anhydrous ethanol, place on a decolorizing shaker for 20 minutes, and repeat this process twice.
[0114] 11) Aspirate the anhydrous ethanol, add a mixture of 50% ethanol and 50% xylene, and place on a decolorizing shaker for 30 minutes.
[0115] 12) Aspirate the solution, add xylene, and place on a decolorizing shaker for 10 minutes. Repeat this process twice.
[0116] 13) Soak the organoid gel in melted wax (wash off the xylene), then immerse it in a six-well plate filled with wax. It can be embedded after 2 hours and can be placed in a refrigerator to accelerate the solidification of the wax block.
[0117] 8. HE staining and image scanning of organoids
[0118] 1) Place all slides to be stained into the staining rack. To prevent detachment, place the paraffin sections in a 60°C oven for 2 hours before staining.
[0119] 2) Dewaxing the paraffin sections. The staining rack with the slides was first immersed in xylene and fresh xylene for 10 min, then immersed in anhydrous ethanol for 10 min, and finally immersed in 95% ethanol, 80% ethanol and 70% ethanol for 5 min respectively.
[0120] 3) Remove the slices from the 70% ethanol and rinse gently with water, then soak in distilled water for 5 minutes, and then soak in clean distilled water for 5 minutes.
[0121] 4) Hematoxylin staining: Shake off the water droplets on the slices, put them into hematoxylin staining solution for 5 minutes, and rinse them thoroughly with tap water.
[0122] 5) In order to remove the excess dye bound to the nucleus and cytoplasm, differentiation is required after hematoxylin staining. Remove the slices and place them in hematoxylin differentiation solution for 5 seconds, then rinse thoroughly with running water.
[0123] 6) To adjust the hematoxylin staining, the sample needs to be blued. Place the sample in the hematoxylin bluing solution for 5 seconds and rinse thoroughly with tap water.
[0124] 7) Eosin staining: The sections were dehydrated in 85% ethanol for 5 min, 95% ethanol for 5 min, eosin staining solution for 5 min, rinsed thoroughly with tap water, and then dehydrated in anhydrous ethanol and fresh anhydrous ethanol for 5 min each.
[0125] 8) Transparency: Dehydrate the sections with fresh anhydrous ethanol for 5 minutes, then soak in xylene and fresh xylene for 5 minutes each.
[0126] 9) Sealing: Add neutral gum (can be diluted with xylene) for sealing.
[0127] 10) After a series of related operations of staining, use a slide scanning imaging system to scan and use ImageViewer software for image analysis.
[0128] 9. Results
[0129] 9.1 Paclitaxel IC in Bladder Cancer Organoids 50 Value Test
[0130] Before inducing organoids to resist drug, drug sensitivity tests were performed to test their tolerance to paclitaxel. In this experiment, six drug concentrations were set. After six days of drug action, the drug sensitivity curves were obtained by fitting. Figure 1 A to C), ICs corresponding to three organoids 50 The values were 6.56nM, 6.59nM and 4.04nM ( Figure 1 D) Initial IC of three organoids 50 The value is used as a reference for the subsequent setting of the concentration for inducing drug resistance.
[0131] 9.2 Construction of Paclitaxel-resistant Organoids for Bladder Cancer
[0132] Initial paclitaxel IC values of three organoids 50 The value is a reference for inducing organoid resistance. The initial dosing concentration is close to IC 50 The drug concentrations selected for the three organoids were 7nM, 7nM, and 5nM, respectively. After the organoids adapted, the paclitaxel concentration was gradually increased. The drug concentration and corresponding drug administration time of each organoid are shown in the figure ( Figure 2 During this process, whether to increase the drug concentration is mainly determined by observing the growth status of the organoids. If the organoids gradually adapt to the current drug concentration and maintain a good growth state, they can enter the next dosing phase. According to the pattern of 2-3 days of dosing and 3-4 days of stopping the drug, the entire process of inducing drug resistance lasts about 6 to 7 months.
[0133] 9.3 Inducing drug resistance in bladder cancer organoids based on drug concentration escalation method
[0134] In the process of inducing drug resistance, the IC of organoids before and after drug addition was compared. 50 The IC values of each organoid were tested before and after drug addition. 50 The comparison revealed that the IC 50 The values were partially increased, and then the drug concentration was continued to increase to improve its drug resistance ( Figure 3 After 6-7 months of drug resistance induction, 3 paclitaxel-resistant bladder cancer organoids were finally obtained ( Figure 4 AC), the IC of three organoids was calculated 50 The values have changed significantly and the drug resistance index (RI) is greater than 3 ( Figure 4 D), which can be used for subsequent research on drug resistance mechanisms.
[0135] 9.4 Morphological identification of drug-resistant organoids
[0136] After obtaining paclitaxel-resistant organoids through drug induction, the morphological changes of the organoids were observed and compared under a microscope ( Figure 5 In the figure (A), the morphology of drug-resistant organoids is basically the same as that of drug-untreated organoids. Due to long-term drug treatment, the volume of drug-resistant organoids is smaller than that of drug-untreated organoids. In addition, HE staining also shows the morphological changes of organoids before and after drug resistance ( Figure 5 Middle B). The drug-resistant organoids still retain some tumor characteristics of the initial non-drug-induced organoids, such as nuclear hyperchromasia and increased nuclear-cytoplasmic ratio. However, compared with the initial organoids, the cells in the drug-resistant organoids are more sparsely arranged.
[0137] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for establishing a paclitaxel-resistant organoid model of bladder cancer, characterized in that: The following steps are involved: Isolation of organoids from fresh bladder cancer tissue; Paclitaxel IC in organoids 50 The organoid is cultured for drug resistance induction with the initial drug concentration as the value, so as to obtain initial drug-resistant organoid; The initial drug-resistant organoids were induced to culture again with drug resistance using the drug concentration increasing method to obtain a paclitaxel-resistant organoid model of bladder cancer.
2. The method according to claim 1, characterized in that: The method for isolating organoids from fresh bladder cancer tissue comprises digesting the fresh bladder cancer tissue with a first digestion solution until it is transparent, neutralizing it, digesting the transparent bladder cancer tissue with a second digestion solution, and neutralizing it again to obtain the organoids; The first digestion solution is an aqueous solution containing the following components: 2-10 mg / ml collagenase II, 5-20 μM small molecule inhibitor Y27632, 50-200 μg / ml DNase I and 1-5 mg / ml neutral protease; The second digestive solution is an aqueous solution containing the following components: 50% to 100% by mass concentration of a stable trypsin replacement enzyme and 5 to 20 μM of a small molecule inhibitor Y27632; The neutralization solution for neutralization treatment is based on DMEM culture medium and also includes the following components in volume percentage: 10% to 20% fetal bovine serum and 0.8% to 1.2% acrylic acid.
3. The method according to claim 2, characterized in that: The temperature condition of the first digestion liquid digestion is 36-38°C water bath, and the time is 30-60min; The second digestion solution digestion method is to incubate in a water bath at 36-38°C for 4-6 minutes.
4. The method according to claim 1, characterized in that: Paclitaxel IC of the Organoids 50 The value is 4~7nM.
5. The method according to claim 1, characterized in that: The method of drug resistance induction culture is to perform cyclic culture according to a cycle of first administering the drug for 2 to 3 days and then stopping the drug for 3 to 4 days; The drug resistance induction culture lasts for 6 to 7 months.
6. The method according to claim 1, characterized in that: The concentrations of paclitaxel used to induce drug-resistant culture again are 7-10 nM, 10-13 nM and 16-19 nM respectively; The total time of the re-induction of drug-resistant culture lasts for 6 to 7 months.
7. The method according to any one of claims 1 to 6, characterized in that: After the second neutralization treatment, the product of the neutralization treatment is also removed from impurities.
8. The method according to claim 7, characterized in that: The impurity removal method is membrane filtration and collecting the filtrate; The pore size of the filter membrane is 75 μM or 100 μM.
9. The bladder cancer paclitaxel-resistant organoid model obtained by the method of any one of claims 1 to 8, characterized in that: Resistant to paclitaxel.
10. Use of the paclitaxel-resistant bladder cancer organoid model according to claim 9 in screening or developing anti-tumor drugs.
